// App-Quantinova.ai

108 : Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

Researchers

Presenter

  • Jean-Yves Pierga

Principal Investigators

  • Francois-Clement Bidard

  • Aurelie Autret

  • Thomas Denis Bachelot

  • Pierre Kerbrat

  • Emmanuelle Charafe-Jaufret

  • Jerome Lemonnier

  • Florence Dalenc

  • Christelle Levy

  • Jean-Marc Ferrero

  • Gilles Romieu

  • Jacques Bonneterre

  • Florence Lerebours

  • Patrice Viens

  • Thierry Petit

  • Fabrice Andre

Medical Centers

  • Department d'Oncologie Medicale, Centre Antoine Lacassagne, Nice, France

  • Department of Medical Oncology, Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France

  • Institut Paoli-Calmettes, Marseille, France

  • UNICANCER, Paris, France

  • Institut Gustave Roussy, Villejuif, FranceCentre Leon Berard, Lyon, FranceMedical Oncology Eugene Marquis Comprehensive Cancer Center, Rennes, France

  • Institut du Cancer de Montpellier/Val dAurelle Centre Val d'Aurelle-Paul Lamarque, Montpellier, France

  • Institut Curie, Paris Cedex, France

  • Centre Oscar Lambret, Lille, France

  • Institut Paoli-Calmettes, Marseille, France

  • Centre Francois Baclesse, Caen, France

  • Institut Claudius Regaud, Toulouse, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 105 Antigen

  • Epithelial Cell Adhesion Molecule

  • Melanoma Cell Adhesion Molecule

Drug/Treatment

  • Bevacizumab

  • Trastuzumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved